Patritumab deruxtecan (HER3-DXd) in early-stage HR+/HER2-breast cancer: Final results of the SOLTI TOT-HER3 window of opportunity trial

被引：8

作者：

Prat, A. ^{[1
]}

Falato, C. ^{[2
]}

Pare Brunet, L. ^{[3
]}

Martinez Saez, O. ^{[4
]}

Cejalvo Andujar, J. M. ^{[5
]}

Margeli Vila, M. ^{[6
]}

Tolosa, P. ^{[7
]}

Salvador Bofill, F. J. ^{[8
]}

Cruz Jurado, J. ^{[9
]}

Gonzalez-Farre, B. ^{[10
]}

Sanfeliu Torres, E. ^{[10
]}

Ciruelos, E. M. ^{[11
]}

Espinosa-Bravo, M. ^{[12
]}

Izarzugaza Peron, Y. ^{[13
]}

Pernas Simon, S. ^{[14
]}

Esker, S. ^{[15
]}

Fan, P-D. ^{[16
]}

Ferrero Cafiero, J. M. ^{[17
]}

Pascual, T. ^{[18
]}

Oliveira, M. ^{[19
]}

机构：

[1] Hosp Clin Barcelona SOLTI IDIBAPS, Dept Med Oncol, Barcelona, Spain

[2] IDIBAPS August Pi Sunyer Biomed Res Inst, SOLTI Canc Res Grp, Barcelona, Spain

[3] SOLTI Canc Res Grp, Data Management, Barcelona, Spain

[4] Hosp Clin Barcelona, Dept Med Oncol, SOLTI Canc Res Grp, Barcelona, Spain

[5] Hosp Clin Univ Valencia, Dept Med Oncol, SOLTI Canc Res Grp, Valencia, Spain

[6] ICO Inst Catala Oncol Badalona Hosp Univ Germans, Dept Med Oncol, SOLTI Canc Res Grp, Badalona, Spain

[7] Inst Invest Sanitaria Hosp 12 Octubre, Dept Med Oncol, SOLTI Canc Res Grp, Madrid, Spain

[8] Hosp Univ Virgen Valme, Med Oncol, Seville, Spain

[9] Hosp Univ Canarias, Dept Med Oncol, San Cristobal, Spain

[10] Hosp Clin Barcelona, Pathol Dept, SOLTI Canc Res Grp, Barcelona, Spain

[11] Hosp Univ 12 Octubre, Dept Med Oncol, SOLTI Canc Res Grp, Madrid, Spain

[12] Vall dHebron Univ Hosp, Breast Surg Unit, Barcelona, Spain

[13] Hosp Univ Fdn Jimenez Diaz, Dept Oncol, Madrid, Spain

[14] ICO Inst Catala Oncol Hosp Hosp Duran, Dept Med Oncol, SOLTI Canc Res Grp, Lhospitalet De Llobregat, Spain

[15] Daiichi Sankyo Inc, Global Med Dept, Basking Ridge, NJ USA

[16] Daiichi Sankyo Pharma Dev USA, Global Oncol, Edison, NJ USA

[17] SOLTI Canc Res Grp, Dept Clin Res, Barcelona, Spain

[18] Hosp Clin Barcelona, Dept Med Oncol, SOLTI Canc Res Grp, Barcelona, Spain

[19] Vall dHebron Inst Oncol VHIO, SOLTI Canc Res Grp, Breast Canc Unit, Barcelona, Spain

来源：

ANNALS OF ONCOLOGY | 2022年 / 33卷

关键词：

D O I：

10.1016/j.annonc.2022.03.279

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA3

引用

页码：S164 / S164

页数：1

共 50 条

[31] Efficacy and safety of patritumab deruxtecan (HER3-DXd) in advanced/metastatic non-small cell lung cancer (NSCLC) without EGFR-activating mutations.
Steuer, Conor Ernst
Hayashi, Hidetoshi
Su, Wu-Chou
Nishio, Makoto
Johnson, Melissa Lynne
Kim, Dong-Wan
Koczywas, Marianna
Felip, Enriqueta
Gold, Kathryn A.
Murakami, Haruyasu
Baik, Christina S.
Kim, Sang-We
Smit, Egbert F.
Gigantone, Mark
Kim, Ben
Fan, Pang-Dian
Qi, Zhenhao
Wu, Elaine Y.
Sternberg, David W.
Janne, Pasi A.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[32] PIK3CA mutational status in tissue & plasma as a prognostic tool in HR+/HER2-breast cancer (BC)
Brage, Eduardo Teran
Mejorada, Rebeca Lozano
Francoso, Aline Rodrigues
Leon, Jose Antonio Munoz
Gutierrez, Alvaro Lopez
Figuero-Perez, Luis
Araujo, Daniel Morchon
Martinez, Maria Garijo
Ruiz, Jonnathan Roldan
Hernandez, Maria Mar Abad
de Salas, Magdalena Sancho
Sanchez, Emilio Fonseca
Sanchez, Cesar Augusto Rodriguez
CANCER RESEARCH, 2024, 84 (09)
[33] HERTHENA-Lung01: A randomized phase 2 study of patritumab deruxtecan (HER3-DXd) in previously treated metastatic EGFR-mutated NSCLC.
Janne, Pasi A.
Johnson, Melissa L.
Goto, Yasushi
Yang, James Chih-Hsin
Vigliotti, Michele
Dong, Qian
Qiu, Yang
Yu, Channing
Yu, Helena Alexandra
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[34] Efficacy and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC).
Janne, Pasi A.
Baik, Christina S.
Su, Wu-Chou
Johnson, Melissa Lynne
Hayashi, Hidetoshi
Nishio, Makoto
Kim, Dong-Wan
Koczywas, Marianna
Gold, Kathryn A.
Steuer, Conor Ernst
Murakami, Haruyasu
Yang, James Chih-Hsin
Kim, Sang-We
Vigliotti, Michele
Qi, Zhenhao
Qiu, Yang
Zhao, Lihui
Sternberg, David W.
Yu, Channing
Yu, Helena Alexandra
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[35] Comparison of the cost-effectiveness of multigene assays for HR+/HER2-nodenegative early-stage breast cancer in the US
Berdunov, Vladislav
Carter, Gebra Cuyun
Russell, Christy
Campbell, Sara
Racz, Jennifer
Abdou, Yara
CANCER RESEARCH, 2024, 84 (09)
[36] Prognostic value of PIK3CA mutational status in tissue & plasma in HR+/HER2-breast cancer (BC)
Lozano Mejorada, R.
Teran Brage, E.
Munoz Leon, J. A.
Lopez Gutierrez, A.
Figuero Perez, L.
Rodrigues Francoso, A.
Seijas Tamayo, R.
Morchon Araujo, D.
Garijo Martinez, M. D. C.
Roldan-Ruiz, J.
Abad Hernandez, M. M.
Sancho de Salas, M.
Fonseca Sanchez, E.
Rodriguez Sanchez, C. A.
ANNALS OF ONCOLOGY, 2023, 34 : S389 - S389
[37] Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in Locally Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) without EGFR-Activating Mutations
Johnson, M. L.
Steuer, C. E.
Hayashi, H.
Su, W. -C.
Nishio, M.
Kim, D. -W.
Koczywas, M.
Felip, E.
Gold, K. A.
Murakami, H.
Baik, C. S.
Kim, S. -W.
Smit, E. F.
Gigantone, M.
Kim, B.
Fan, P. -D.
Qi, Z.
Wu, E. Y.
Sternberg, D.
Janne, P. A.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (03) : E30 - E31
[38] HERTHENA-Lung01: A Randomized Phase 2 Study of Patritumab Deruxtecan (HER3-DXd; U3-1402) in Previously Treated Metastatic EGFR-mutated NSCLC
Janne, P.
Johnson, M.
Goto, Y.
Yang, J. C.
Karam, S.
Chen, S.
Qiu, Y.
Yu, H.
Yu, C.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S236 - S236
[39] An open-label, phase II study of patritumab deruxtecan (HER3-DXd, U3-1402) in patients (pts) with previously treated advanced/metastatic colorectal cancer (CRC).
Raghav, Kanwal Pratap Singh
Yoshino, Takayuki
Taniguchi, Hiroya
Tejpar, Sabine
Vogel, Arndt
Wainberg, Zev A.
Yamaguchi, Kensei
Kanai, Masayuki
Liu Yali
Mekan, Sabeen
Pudussery, Geetha
Qiu, Yang
Kopetz, Scott
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
[40] The MonarchE trial: improving the clinical outcome in HR+/HER2- early breast cancer: recent results and next steps
Bertucci, Francois
Finetti, Pascal
Mamessier, Emilie
De Nonneville, Alexandre
CANCER COMMUNICATIONS, 2023, 43 (08) : 938 - 942

← 1 2 3 4 5 →